Drug Profile
Research programme: Pompe disease therapeutics - Cartesian Therapeutics
Alternative Names: SVP Rapamycin + Alglucosidase alfaLatest Information Update: 05 Dec 2023
Price :
$50
*
At a glance
- Originator Selecta Biosciences
- Developer Cartesian Therapeutics
- Class Anti-infectives; Anti-inflammatories; Antiepileptic drugs; Antifungals; Antineoplastics; Cardiovascular therapies; Eye disorder therapies; Lactones; Macrolides; Nootropics; Polyenes; Polyketides; Pyridines; Skin disorder therapies
- Mechanism of Action Immunosuppressants; MTOR protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Glycogen storage disease type II
Most Recent Events
- 28 Mar 2021 No recent reports of development identified for preclinical development in Glycogen-storage-disease-type-II in USA (Parenteral)
- 16 Feb 2017 Preclinical trials in Glycogen storage disease type II in USA (unspecified route)